Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Drug Deliv Transl Res. 2018 Aug;8(4):964–984. doi: 10.1007/s13346-017-0419-y

Fig. 7.

Fig. 7

Schematic showing design of DOX-releasing PEG-PLGA methyl ether NPs (A). TEM indicated similar morphology and size of 0% and 10% w/w DOX-loaded PEG-PLGA-methyl ether NPs. A LIVE/DEAD cytotoxicity assay indicated EaRASMCs exposed for 24 h to 0% and 10% w/w DOX-loaded PEG-PLGA-methyl ether NPs (0.2 mg of NPs/mL) to be viable, Scale bar = 100 μm